Skip to main content
HCPCS J9171 · Level II · Part B drug

J9171: docetaxel, HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9171

Billing unit
1 MG
Docetaxel injection
ASP payment limit
$0.471
October 2026; +3.3% vs July 2026
Practitioner MUE
300
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9171 is the Level II code for Injection, docetaxel, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $0.471 per billing unit, up 3.3% from July 2026. The practitioner MUE allows up to 300 units per date of service (MAI 3), so a full 300-unit day is $141.30 at the current limit. Under OPPS it carries status indicator N. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names docetaxel: J9172 (Docivyx from Avyxa Pharma, LLC); J9174 (Beizray from Zydus Pharmaceuticals (USA) Inc); J9232 (the Hospira product (manufacturer named in its CMS descriptor); not therapeutically equivalent to J9171). The ASP crosswalk maps 21 NDCs to it, sold as Docetaxel by Hikma Pharmaceuticals USA Inc., Sanofi-Aventis U.S. LLC, Accord Healthcare Inc. No current Billing and Coding Article lists J9171, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9171 at $0.471 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.456 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9171
QuarterPayment limitPerCoinsurance
October 2026$0.4711 MG20%
July 2026$0.4561 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 21 NDCs from 10 labelers to J9171. Report the NDC in the claim's drug segment and bill the number of J9171 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J9171
NDCDrug nameLabelerPackage sizeBilling units / package
00143-9204-01DocetaxelHikma Pharmaceuticals USA Inc.1 × 120
00143-9205-01DocetaxelHikma Pharmaceuticals USA Inc.4 × 180
00955-1020-01DocetaxelSanofi-Aventis U.S. LLC1 × 120
00955-1021-04DocetaxelSanofi-Aventis U.S. LLC4 × 180
00955-1022-08DocetaxelSanofi-Aventis U.S. LLC8 × 1160
16729-0267-65DocetaxelAccord Healthcare Inc8 × 1160
23155-0903-31DocetaxelHeritage Pharmaceuticals Inc.1 × 120
23155-0904-31DocetaxelHeritage Pharmaceuticals Inc.4 × 180
23155-0905-31DocetaxelHeritage Pharmaceuticals Inc.8 × 1160
25021-0245-01DocetaxelSagent Pharmaceuticals1 × 120
25021-0245-04DocetaxelSagent Pharmaceuticals4 × 180
43066-0046-08DocetaxelBaxter Healthcare Corp.8 × 180
43066-0048-16DocetaxelBaxter Healthcare Corp.16 × 1160
45963-0734-54DocetaxelActavis Pharma, Inc.1 × 120
45963-0765-52DocetaxelActavis Pharma, Inc.4 × 180
55150-0379-01DocetaxelEugia US LLC8 × 180
55150-0380-01DocetaxelEugia US LLC16 × 1160
67457-0781-08DocetaxelMylan Institutional LLC8 × 1160
70121-1221-01DocetaxelAmneal Pharmaceuticals, LLC1 × 120
70121-1222-01DocetaxelAmneal Pharmaceuticals, LLC4 × 180
70121-1223-01DocetaxelAmneal Pharmaceuticals, LLC8 × 1160

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9171. For practitioners the limit is 300 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9171 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services3003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital3003 Date of Service Edit: ClinicalPrescribing Information
DME supplier3003 Date of Service Edit: ClinicalPrescribing Information

MUE for J9171 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9171 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9171 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9171 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9171 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9171 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9171 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J9171 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9171

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9171

What does HCPCS code J9171 describe?

J9171 is defined by CMS as "Injection, docetaxel, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9171 a CPT code?

No. J9171 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as docetaxel; CPT codes are five-character codes maintained by the AMA. On a Part B claim J9171 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9171 in October 2026?

The ASP-based payment limit is $0.471 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $0.456. Commercial payers use their own fee schedules.

How many units of J9171 can be billed per day?

The practitioner Medically Unlikely Edit is 300 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J9171?

The October 2026 ASP crosswalk lists 21 NDCs from 10 labelers: Docetaxel (Hikma Pharmaceuticals USA Inc.); Docetaxel (Sanofi-Aventis U.S. LLC); Docetaxel (Accord Healthcare Inc); Docetaxel (Heritage Pharmaceuticals Inc.). For example NDC 00143-9204-01 (package size 1) equals 20 billing units of J9171.

Does J9171 have NCCI bundling edits?

No active practitioner PTP pairs list J9171 as a column-1 or column-2 code in the v323r0 release.

J9171 vs J9172: what is the difference?

Both are HCPCS Level II codes whose descriptor names docetaxel. What sets J9172 apart: Docivyx from Avyxa Pharma, LLC. J9171 is billed per 1 mg, limit $0.471, MUE 300; J9172 is billed per 1 mg, limit $46.193, MUE 300. Report the code whose descriptor matches the product and setting in the record.

J9171 vs J9174: what is the difference?

Both are HCPCS Level II codes whose descriptor names docetaxel. What sets J9174 apart: Beizray from Zydus Pharmaceuticals (USA) Inc. J9171 is billed per 1 mg, limit $0.471, MUE 300; J9174 is billed per 1 mg, limit $46.531, MUE 320. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.